ALNY

Alnylam Pharmaceuticals (ALNY) is the lead sponsor of 22 active clinical trials listed on ClinicalTrials.gov^[4], including 6 Phase 3^[1], 5 Phase 2^[2], 8 Phase 1^[3].

Trial NCT06679946^[5] evaluates Vutrisiran in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy with a target enrollment of 700 participants. Trial NCT07223203^[6] evaluates Nucresiran in Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy with a target enrollment of 125 participants. Trial NCT07181109^[7] evaluates Zilebesiran in High Risk Cardiovascular Disease with a target enrollment of 11000 participants.

ALNY has 1 Form 4 insider filing recorded at the SEC in the past 30 days^[8].